Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2025-05-23 00:00:00 ET · period of report 2025-05-21 · accession 0001062993-25-010155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-05-23 | 2025-05-21+ | PHIO | Bitterman Robert J | COB, Pres, CEO, Dir | P - Purchase | $1.77 | +4,200 | 22.4K | +23% | +$7,446 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.0001 par value | 2025-05-22 | P | A | 1,200 | $1.78 | 23,649 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. (F2) The number of reported securities has been adjusted to reflect prior reverse stock splits. |
| 2 | Common | Common Stock, $0.0001 par value | 2025-05-21 | P | A | 3,000 | $1.77 | 22,449 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. (F2) The number of reported securities has been adjusted to reflect prior reverse stock splits. |